3 completed, 2 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Asceneuron S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ASN51 in Adults With Early Alzheimer's Disease ASN51, Placebo - Alzheimer Disease | Phase 2 | Terminated | Asceneuron S.A. | 123 | 2024-10-16 | 2025-06-29 |
| Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects Fluvoxamine, Itraconazole, Paroxetine - Drug Drug Interaction | Phase 1 | Completed | Asceneuron S.A. | 50 | 2024-02-22 | 2024-12-18 |
| PET Study of Repeated ASN51 in Healthy Volunteers ASN51 - Healthy | Phase 1 | Completed | Asceneuron S.A. | 12 | 2023-01-26 | 2025-05-08 |
| Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51 ASN51 - Healthy Participants | Phase 1 | Completed | Asceneuron S.A. | 3 | 2021-08-09 | 2025-05-08 |
| Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease ASN51, Placebo - Alzheimer Disease | Phase 1 | Terminated | Asceneuron Pty Ltd. | 25 | 2021-06-02 | 2023-01-17 |
Fluvoxamine (1) · Itraconazole (1) · Paroxetine (1)
United Kingdom (2) · Australia (1) · Netherlands (1) · United States (1)
Adeep Puri, MD (1) · Rolf Pokorny, MD (1)